A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

June 2, 2016

Primary Completion Date

May 31, 2018

Study Completion Date

November 19, 2018

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
DRUG

Placebo

Solution for infusion, 0,9% saline

DRUG

Dapirolizumab pegol (DZP)

Solution for infusion

Trial Locations (71)

11042

Sl0023 313, Lake Success

30281

Sl0023 327, Stockbridge

30303

Sl0023 324, Atlanta

32713

Sl0023 322, DeBary

33014

Sl0023 301, Miami Lakes

33136

Sl0023 321, Miami

33603

Sl0023 310, Tampa

33765

Sl0023 304, Clearwater

34684

Sl0023 319, Palm Harbor

35294

Sl0023 312, Birmingham

38119

Sl0023 308, Memphis

38305

Sl0023 315, Jackson

73101

Sl0023 305, Oklahoma City

77034

Sl0023 303, Houston

79124

Sl0023 317, Amarillo

83404

Sl0023 320, Idaho Falls

87104

Sl0023 306, Albuquerque

90048

Sl0023 311, Los Angeles

91360

Sl0023 314, Thousand Oaks

91786

Sl0023 302, Upland

92020

Sl0023 307, El Cajon

Sl0023 309, El Cajon

92646

Sl0023 323, Huntington Beach

99204

Sl0023 328, Spokane

06520

Sl0023 326, New Haven

Unknown

Sl0023 101, Plovdiv

Sl0023 102, Plovdiv

Sl0023 202, Providencia

Sl0023 203, Providencia

Sl0023 201, Puerto Varas

Sl0023 204, Viña del Mar

Sl0023 213, Barranquilla

Sl0023 212, Bogotá

Sl0023 214, Bogotá

Sl0023 216, Bucaramanga

Sl0023 211, Chía

Sl0023 215, Medellín

Sl0023 341, Hanover

Sl0023 113, Leipzig

Sl0023 124, Debrecen

Sl0023 225, Guadalajara

Sl0023 224, León

Sl0023 221, México

Sl0023 222, San Luis Potosí City

Sl0023 232, Arequipa

Sl0023 231, Lima

Sl0023 234, Lima

Sl0023 235, Lima

Sl0023 133, Bytom

Sl0023 138, Lodz

Sl0023 136, Lublin

Sl0023 131, Poznan

Sl0023 134, Sosnowiec

Sl0023 135, Warsaw

Sl0023 146, Brasov

Sl0023 142, Bucharest

Sl0023 144, Cluj-Napoca

Sl0023 141, Galati

Sl0023 157, Kazan'

Sl0023 156, Kemerovo

Sl0023 152, Saint Petersburg

Sl0023 155, Voronezh

Sl0023 151, Yaroslavl

Sl0023 153, Yekaterinburg

Sl0023 161, Barcelona

Sl0023 162, Madrid

Sl0023 166, Santa Cruz de Tenerife

Sl0023 172, Kyiv

Sl0023 175, Kyiv

Sl0023 171, Odesa

Sl0023 173, Vinnytsia

All Listed Sponsors
lead

UCB Biopharma S.P.R.L.

INDUSTRY

NCT02804763 - A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter